GRCE Grace Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1444192 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-173.9%
TTM EPS YoY-118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-36.2%
ROA-34.5%
ROIC (approx.)-46.7%
Asset turnover—
Leverage & solvency
Liabilities / assets3.8%
Debt / equity0.00x
Current ratio13.61x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-20.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $100.00M |
| Cost of revenue | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $100.00M |
| R&D expense | $2.40M | $9.51M | $4.68M | $9.97M | $5.56M |
| SG&A expense | $8.67M | $7.17M | $6.68M | $7.61M | $9.26M |
| Operating income | -$11.08M | -$16.68M | -$12.85M | -$52.16M | -$15.59M |
| Pretax income | -$9.49M | -$12.77M | -$14.69M | -$51.97M | -$10.47M |
| Income tax | -$1.70M | -$3.20M | -$1.83M | -$9.54M | -$648,000 |
| Net income | -$7.79M | -$9.57M | -$12.85M | -$42.43M | -$9.82M |
| EBITDA | -$11.07M | -$16.67M | -$12.84M | -$52.03M | -$15.59M |
| EPS (basic) | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 |
| EPS (diluted) | -0.47 | -0.79 | -1.35 | -5.71 | -0.27 |
| Weighted avg. shares (diluted) | 16.51M | 12.09M | 9.53M | 7.44M | 36.84M |
| Balance sheet | |||||
| Cash & equivalents | $16.98M | $22.13M | $23.00M | $27.88M | $30.34M |
| Short-term investments | — | — | $0 | $15,000 | $13.32M |
| Receivables | — | — | $722,000 | $802,000 | $548,000 |
| Current assets | $17.38M | $22.71M | $24.01M | $29.29M | $45.28M |
| PP&E, net | $8,000 | $15,000 | $24,000 | $104,000 | $20.89M |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $12.96M |
| Intangibles | $41.13M | $41.13M | $41.13M | $41.13M | $69.81M |
| Total assets | $66.65M | $71.99M | $73.30M | $79.12M | $128.62M |
| Current liabilities | $2.15M | $1.93M | $1.68M | $3.41M | $3.26M |
| Total liabilities | $2.76M | $5.38M | $11.56M | $11.17M | $20.35M |
| Shareholders' equity | $63.90M | $66.61M | $61.74M | $67.95M | $108.27M |
| Shares outstanding | 16.02M | 13.72M | 9.40M | 7.44M | 44.29M |
| Cash flow statement | |||||
| Operating cash flow | -$8.87M | -$14.90M | -$12.33M | -$15.91M | -$17.23M |
| Investing cash flow | $0 | $0 | $104,000 | $13.15M | -$3.52M |
| Financing cash flow | $3.71M | $14.03M | $7.36M | $304,000 | $0 |
| Depreciation & amortization | $7,000 | $7,000 | $11,000 | $124,000 | $0 |
| Stock-based compensation | $798,000 | $730,000 | $913,000 | $1.81M | $1.34M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.